Will you consider additional capecitabine in a patient with TNBC, residual disease after neo-adjuvant chemo, before getting adjuvant pembrolizumab or placebo on SWOG 1418 clinical trial?  

We offered adjuvant capecitabine to our TNBC patients with residual disease after neoadjuvant chemo prior to enrolling them on our adjuvant immunotherapy clinical trials. 

I would first offer EA 1131 (ECOG-ACRIN) comparing adjuvant capecitabine vs platinum chemotherapy. If she is not eligible, then I would consider adjuvant capecitabine off trial.  After adjuvant chemotherapy, or if declined, I would then offer the SWOG 1418 study.  I do not believe capecita...

I would definitely offer capecitabine before enrolling them on SWOG 1418. We already have data that capecitabine improves outcomes in TNBC with residual disease after neoadjuvant chemotherapy. I would not feel comfortable depriving a patient from a therapy that has proven beneficial in the phase III...